Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22062857 | 0.82 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25402495 | 0.82 | L3MBTL1 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25402492 | 0.82 | L3MBTL1 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL21066543 | 0.82 | NPC1 (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1695235 | 0.81 | NPC1 (0.66) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20495657 | 0.80 | MEN1 (0.63) | ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL20578306 | 0.79 | L3MBTL1 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20578308 | 0.79 | L3MBTL1 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6237220 | 0.78 | LDHA (0.57) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28049334 | 0.78 | LDHA (0.57) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089126-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| EP-3735299-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | ALDH1A1 3258/4885NPC1 952/4885RAB9A 57/4885 |
| US-20230089126-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | ALDH1A1 3258/4885NPC1 952/4885RAB9A 57/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | ALDH1A1 3258/4885NPC1 952/4885RAB9A 57/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | ALDH1A1 3258/4885NPC1 952/4885RAB9A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.